Reaction
Neuroendocrine Carcinoma reporting signals
As of the last recalculation, Neuroendocrine Carcinoma appears in 687 FAERS reports alongside 11 co-occurring drug terms. The strongest observed disproportionality signal is OCTREOTIDE ACETATE (PRR 55.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Octreotide Acetate | 52 | 55.6 | 55.7 |
| Bicalutamide | 11 | 22.2 | 22.2 |
| Etoposide | 37 | 16.1 | 16.1 |
| Gefitinib | 4 | 13.5 | 13.5 |
| Apalutamide | 5 | 13.0 | 13.0 |
| Erlotinib | 4 | 12.6 | 12.6 |
| Durvalumab | 7 | 10.5 | 10.5 |
| Temozolomide | 7 | 10.2 | 10.2 |
| Ranitidine Hydrochloride | 17 | 9.7 | 9.7 |
| Lutetium Lu 177 Vipivotide Tetraxetan | 4 | 9.2 | 9.2 |
| Olaparib | 5 | 7.3 | 7.3 |